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Risk of cardiovascular events and cyclooxygenase-2 inhibitors
Selective cyclooxygenase-2 (Cox-2) inhibitors have been at the centre of public
attention since the revelation that the use of these drugs is associated with an increased
risk of cardiovascular events (Tabrizchi 2005). Certainly pharmaco vigilance has an
important place in the public domain and any new therapeutic information that leads
to an increased level of physician–patients awareness has to be received with high
degree of priority.
Recently, Caldwell and colleagues (2006) provided a systemic review and meta-
analysis of double-blind, randomized, controlled studies of celecoxib to assess the
risk of cardiovascular events. The primary goal was a comparative assessment of
celecoxib with placebo, whereas the secondary analysis evaluated celecoxib versus
placebo together with other non-steroidal antiinflammatory drugs (eg, diclofenac,
ibuprofen, and paracetamol). Six studies were included in this analysis that met the
criteria with the total sample size of 4422 and 12 780 for the primary and secondary
analysis, respectively. Data was included from trials evaluating treatment of medical
conditions including rheumatoid arthritis, osteoarthritis, Alzheimer’s disease, and
the prevention of colorectal adenoma. The authors conclude that the increased risk
of myocardial infarction observed with the use of celecoxib is consistent with this
class of drugs (Caldwell et al 2006).
While great emphasis has been placed on the incidence of cardiovascular events,
the risk of vascular events is not evenly distributed between myocardial infarction
and cerebrovascular events. The incidence for cardiovascular events in this is recent
meta-analysis was revealed to be 1.13% (n=2574) in subjects taking celecoxib in
comparison with 0.41% (n=1447) in subjects on placebo with an odds ratio (OR) of
2.26 (95% confidence interval [CI] 1.0–5.1) for myocardial infarction. In contrast,
the incidence of cerebrovascular events recorded was 0.86% (n=2775) in subjects
on celecoxib versus 0.79% (n=1647) in subjects taking placebo with an OR 1.0 (95%
CI 0.51–1.84) (Caldwell et al 2006). Thus the risk of crebrovascular events is not
comparable with the risk of myocardial infarction with use of this drug.
This finding is not unique to celecoxib and has been reported for rofecoxib as
well, where the combined relative risk of myocardial infarction for rofecoxib in
comparison with control was 2.24 (95% CI 1.24–4.02) (Jüni et al 2004). This contrasts
with the occurrence of stroke in which the relative risk was 1.02 (95% CI 0.54–1.93)
for rofecoxib versus control (Jüni et al 2004).
This class of drugs produce their beneficial effects by selective inhibition of the
Cox enzyme. Cox-1 and Cox-2 are the isozymes involved in the catabolism of
eicosanoids from arachidonic acid. Within the cascade responsible for the production
of the various eicosanoids are two metabolites, prostaglandin I2 (PGI2) and
thromboxane A2 (TxA2) which have critical roles on blood vessel function. While
the latter compound is a potent vasoconstrictor and is a promoter of platelet
aggregation, the former is a vasodilator and an inhibitor of platelet aggregation
(Catella-Lawson 2001). However, it is also believed that Cox-2 is the enzyme mainly
responsible for the production of PGI2 while Cox-1 plays a more central role in the
biosynthesis of TxA2 (Vinals et al 1997; Brock et al 1999; Catella-Lawson et al
1999; McAdam et al 1999). Therefore, it is prudent to assume that selective inhibition
of Cox-2 could change the balance between the production of PGI2 and TxA2 shiftingVascular Health and Risk Management 2006:2(2) 96
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it towards a higher levels of the latter molecule. This would
be expected to increase the risk of vasospasm and
thromboembolism and thus increase the risk of
cardiovascular events (ie, myocardial infarction).
Surprisingly, it seems that while there is some evidence
to suggest that the use of Cox-2 inhibitors such as rofecoxib
and celecoxib increase the incidence of myocardial
infarction, the same cannot be said about cerebrovascular
events (Jüni et al 2004; Caldwell et al 2006). There are two
important questions that readily come to mind. First, is the
observation that therapy with selective Cox-2 inhibitors
increases the risk of myocardial infarction, but not that of
stroke real? Second, if the latter concept is true, what is the
basis of this difference? Certainly, there are functional
differences between brain and heart blood vessels. It is also
recognized that coronary blood vessels experience excessive
wall stress and it is possible that overall they are more
sensitive to the reduction in the levels of PGI2 as well as
being more sensitive to the detrimental actions of TxA2
during the inhibition of Cox-2 enzyme. Alternatively,
cerebral blood vessels may have the inherent ability to
overcome the selective inhibition exhibited by Cox-2
inhibitors and thus have the capability to restore the
functional imbalance that occurs following the reduction in
PGI2 and provide the counter balance to overcome the
physiological effects of TxA2. Moreover, a combination of
different structural and metabolic demands placed on each
vessel together with differences in the functional behavior
as well as the location of each vessel forms the basis for
this disparity and in making one vessel less at risk of vascular
events in contrast to the other. Clearly there is inadequate
information for a succinct answer to this anomaly, and
obviously the issue requires further in-depth investigation.
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